The firm is pleased to sponsor the 15th Summit on Biosimilars & Innovator Biologics, which will be hosted by ACI at the New York Bar Association from June 20 to 21, 2024. Director JC Rozendaal will be a speaker on the “Implications for Product Launch and Market Exclusivity: Decoding In Re Cellect, USPTO Guidance on Patent Term Adjustments and OTDP” panel on June 20, 2024.

Panel Overview

  • Understanding how product launches are influenced by PTE and OTDP
  • Unpacking the In Re Cellect federal circuit arguments and decision
    • Reading the tea leaves on what this case will mean for the future of patent term adjustment strategy
  • Appreciating the interplay between obviousness type double patenting and In re Cellect
  • Emphasizing strategies in drafting claims for first filed and subsequent continuation applications to avoid OTDP concerns
    • Maintaining safe harbor of a divisional all the way through versus filing all at once and re-dividing down the line
  • Unpacking the USPTO’s Guidance on obviousness rejections
  • Updating patent adjustment forecasts to biologic or biosimilar launch timelines

Related Industries